Wird Atherosklerose bei extrem niedrigen lebenslangen LDL-Spiegeln biologisch eliminiert?

Eine kritische Bewertung der “Null-Risiko”-Hypothese

atherosklerotisch Herz-Kreislauf-ErkrankungHerz-Kreislauf-Erkrankungen sind der Oberbegriff für Probleme mit dem Herzen und den Blutgefäßen, einschließlich Herzinfarkten, Schlaganfällen und verstopften Beinarterien. (ASCVD) wurde lange Zeit als unvermeidliche Folge der menschlichen Alterung angesehen, jedoch werfen die zeitgenössische Molekularbiologie und Genetik EpidemiologieEpidemiologie ist die Erforschung von Gesundheitstrends in großen Bevölkerungsgruppen – wer erkrankt, wo und was diese Personen gemeinsam hatten. nehmend auf ein substratabhängiges Modell konvergieren, in dem die Krankheit im Prinzip biologisch vermeidbar ist1], [2]. Die Prämisse der “Null-Risiko”-Hypothese ist, dass AtheroskleroseAtherosklerose ist die Erkrankung, die den meisten Herzinfarkten und vielen Schlaganfällen zugrunde liegt. Cholesterinteilchen bleiben in der Wand einer Arterie stecken, der Körper schickt Immunzellen zur Beseitigung, und über Jahre hinweg verhärtet sich dieses Chaos zu Plaque. ist in erster Linie ein ApolipoproteinEin Apolipoprotein ist ein Protein, das an ein fetttransportierendes Partikel in Ihrem Blut gebunden ist. Da Fett und Wasser sich nicht mischen, wirken diese Proteine wie eine Hülle, die es dem Fett ermöglicht, sicher durch den Blutkreislauf zu reisen. BApoBApoB ist ein Protein, das sich auf der Außenseite jedes Cholesterinteilchens befindet, das in Ihrer Arterienwand stecken bleiben und Plaque verursachen kann. Jedes dieser Teilchen trägt genau ein ApoB.)-gesteuertes Störungsbild2], [3durch die Aufrechterhaltung einer lebenslangen Exposition gegenüber ultra-niedrigen Werten an niedriger Dichte LipoproteinEin Lipoprotein ist ein winziges Paket, das Fett und Cholesterin durch Ihren Blutkreislauf transportiert. Da sich Fett nicht in Wasser löst, benötigt es eine Proteinhülle, um zu reisen. CholesterinCholesterin ist eine wachsartige Substanz, die Ihr Körper braucht. Es fließt in Zellwände, Hormone, Vitamin D und die Galle ein, die Ihre Nahrung verdaut. Ohne es würden Sie sterben. (LDL-C) und seiner entsprechenden ApoB-Partikelkonzentration – etwa 10–20 mg/dL (0,26–0,52 mmol/L), nahe dem physiologischen Neugeborenen-Basiswert – die Wahrscheinlichkeit der Einleitung der pathognomonischA pathognomonic sign is one so specifically characteristic of a particular disease that its presence alone is sufficient to confirm the diagnosis; in HoFH, cutaneous and tendon xanthomas appearing before age four are considered pathognomonic because they are caused by cholesterol spillover so extreme it is almost exclusively seen in this condition. LäsionIn der Kardiologie bezeichnet eine Läsion einen umschriebenen Bereich atherosklerotischer Plaque, der eine Koronararterie verengt und typischerweise durch den Prozentsatz der Lumenobstruktion beschrieben wird, die er verursacht. Der Artikel beschreibt vier Rests Läsionen, deren Gefäßdurchmesser zu gering ist, um nach der Behandlung der kritischsten Läsion einen Stent aufzunehmen. der Atherosklerose (subendotheliale RetentionSubendothelial retention is the process by which ApoB-containing lipoprotein particles that have crossed the endothelial barrier become electrostatically bound to proteoglycans in the arterial intima and are unable to diffuse back into the bloodstream; it is considered the non-redundant first step in atherosclerosis under the response-to-retention framework. der atherogenen Lipoproteine) auf ein biologisch vernachlässigbares Maß gesenkt werden [2], [4]. Dieser Bericht bewertet, ob eine solche extrem geringe Exposition die Krankheitsentstehung wirksam ausschließt oder ob verbleibende Wege, die EntzündungEntzündungen sind die Reaktion Ihres Immunsystems auf eine Verletzung oder etwas, das es als Eindringling behandelt. Sie verursachen Schwellungen, Hitze und Aufräumzellen., Lipoprotein(a)Lipoprotein(a), geschrieben Lp(a) und "L-P-klein-a" ausgesprochen, ist ein LDL-ähnliches Partikel mit einem extra klebrigen Protein daran. [Lp(a)] und Endotheliale DysfunktionEndotheliale Dysfunktion liegt vor, wenn diese dünne Auskleidung ihre Aufgabe nicht mehr gut erfüllt. Die Blutgefäße weiten sich nicht richtig und die Barriere wird durchlässiger. die Fähigkeit behalten, Samen zu bilden arterielle PlaqueA deposit within the artery wall made up of lipids, immune cells, cellular debris, and fibrous tissue that accumulates over time and can narrow or block blood flow; also called an atherosclerotic lesion or atheroma. unabhängig von ApoB5], [6].

Das Response-to-Retention-Modell: Ein deterministisches Framework für die Initialisierung

Die theoretische Grundlage für die biologische Beseitigung der Atherosklerose beruht auf der Response-to-Retention-HypotheseThe response-to-retention hypothesis is the leading mechanistic account of early atherosclerosis, holding that the initiating event is the binding and trapping of apoB-containing lipoprotein particles to proteoglycans in the arterial intima, before inflammation or foam cell formation occurs., welches das subendotheliale Festhalten von ApoB-haltigen Lipoproteinen als das notwendige und hinreichende auslösende Ereignis für identifiziert AtherogeneseAtherogenese ist der schrittweise Prozess der Plaquebildung. [1], [7]. Während traditionelle Modelle eine offene Endothelschädigung als primären Auslöser betonten, zeigt die aktuelle Evidenz, dass ein intaktes, wenngleich dysfunktionales, EndothelThe endothelium is the ultra-thin, slippery lining on the inside of every blood vessel. It is only one cell thick. liegt typischerweise über frühen und intermediären Läsionen1], [8]. Die Krankheitsentstehung beginnt, wenn Lipoproteine mit einem Durchmesser von weniger als ca. 70 nm – einschließlich LDLLDL oder Low-Density-Lipoprotein ist das Hauptpartikel, das Cholesterin durch Ihr Blut transportiert – und das Hauptpartikel, das in den Arterienwänden stecken bleibt., triglyceridreiche Remnants und Lp(a) – die endotheliale Barriere überwinden und in die Tunica IntimaDie Intima ist die innerste Schicht einer Arterienwand und liegt direkt unter der glatten Auskleidung. [2], [7].

Molecular Interactions within the Intimal Matrix

Within the intima, retained particles interact with the extrazelluläre MatrixThe extracellular matrix is the scaffolding of collagen and other fibers that holds tissue together and gives an artery wall its strength. (ECM), particularly with negatively charged proteoglycans such as VersicanVersican is a large sulfated proteoglycan found in the arterial intima whose negatively charged glycosaminoglycan chains bind ionically to apoB-100 on lipoprotein particles, contributing to their retention in the artery wall as an early step in atherosclerosis., perlecan, BiglykanBiglycan is a small leucine-rich proteoglycan present in the arterial subendothelial matrix that, along with versican and decorin, binds apoB-containing lipoprotein particles through ionic interactions, contributing to their retention in the intima as an initiating step in atherosclerosis., and decorin [1], [7]. Positively charged regions of ApoB, specifically sequences rich in lysine and ArgininArginine is an amino acid found in whole foods such as walnuts that serves as the biochemical precursor the body uses to synthesize nitric oxide, thereby supporting endothelial relaxation and healthy blood vessel dilation. residues, bind electrostatically to the GlykosaminoglykanGlycosaminoglycans are long, negatively charged sugar chains that are major components of the arterial extracellular matrix and plaque connective tissue; in cynomolgus macaque plaques they are prominent structural constituents that persist after regression of the lipid-rich components. (GAG) chains of these proteoglycans [1]. This is not passive entrapment; it is a critical biochemical event that prolongs the residence time of the lipoprotein within the arterial wall by an order of magnitude relative to plasma transit [9].

Proteoglycan	Interaction with ApoB Lipoproteins	Role in Atherogenesis
Versican	Large aggregating proteoglycan that expands intimal volume	Promotes lipoprotein trapping and glatte MuskelfasernSmooth muscle cells make up the middle layer of an artery and control how much the vessel tightens or relaxes. migration [7]
Perlecan	Basement-membrane HeparansulfatHeparan sulfate is a negatively charged glycosaminoglycan, similar to chondroitin sulfate, found on proteoglycans in the arterial extracellular matrix; alongside chondroitin sulfate, it participates in the electrostatic binding of ApoB-100–containing lipoproteins that initiates plaque formation. proteoglycan	Structural scaffold facilitating early particle retention [7]
Biglycan	Small leucine-rich proteoglycan with high ApoB affinity	Correlates with development of lipidreicher nekrotischer KernDer lipidreiche nekrotische Kern ist das weiche, mit Fett und Entzündungszellen gefüllte Innere einer fortgeschrittenen atherosklerotischen Plaque; er ist der am stärksten zu Rupturen neigende Bereich und derjenige, der am besten auf eine Lipidsenkung anspricht, die ihn schrumpfen und stabilisieren kann, selbst wenn umgebendes verkalktes Gewebe unverändert bleibt. [7]
Decorin	Interacts with collagen and LDL particles	Modulates fibrotic response and lipoprotein aggregation [7]

Prolonged intimal residence renders retained lipoproteins highly susceptible to chemical modification, including oxidation, glycation, enzymatic cleavage, and aggregation [1], [9]. Modified particles trigger a maladaptive immune response [1], [7]. EndothelzellenThe thin layer of cells lining the inner surface of all blood vessels; they regulate vascular tone, prevent clotting, and control the passage of substances into the artery wall — and their dysfunction is an early, critical step in atherosclerosis. activated by modified lipids and mechanical stressors express adhesion molecules (VCAM-1VCAM-1 is a sticky molecule that appears on an inflamed vessel lining and grabs passing white blood cells so they can burrow into the wall., ICAM-1ICAM-1 is a molecule that appears on the surface of the blood vessel lining and acts like Velcro, catching passing immune cells.) and secrete chemokines that recruit monocytes into the subendothelialer RaumThe subendothelial space is the narrow gap just beneath the artery's inner lining, between that single layer of cells and the muscle beneath. [1], [10]. These monocytes differentiate into MakrophagenEin Makrophage ist eine große Immunzelle, die Zelltrümmer und Eindringlinge umschließt und verschlingt. Der Name bedeutet wörtlich "großer Fresser"." that internalize modified lipoproteins via scavenger receptors and transform into lipid-laden SchaumzellenA foam cell is an immune cell that has eaten so much trapped cholesterol that it swells up and looks foamy under a microscope.—the morphological hallmark of the FettstreifA fatty streak is the earliest visible stage of atherosclerosis — a flat yellow smear of cholesterol-filled immune cells just under the artery lining. [10].

Thermodynamic and Kinetic Limits of Retention

The probability of particle retention is a function of the local concentration of ApoB particles and the availability of Proteoglycan-BindungProteoglycan binding is the electrochemical interaction by which positively charged lysine- and arginine-rich regions of ApoB latch onto the negatively charged glycosaminoglycan chains of intimal matrix proteins such as biglycan, versican, perlecan, and decorin. This binding dramatically prolongs the residence time of a lipoprotein particle within the artery wall, making it far more susceptible t… sites within the matrix [7]. In a stochastic model of the arterial wall, the rate of lipid accumulation is determined by the flux of lipoproteins into the intima and the kinetics of proteoglycan binding [9]. At ultra-low circulating concentrations (e.g., LDL-C ≈ 15 mg/dL), the number of particles available for TranszytoseTranscytosis is the process by which a cell picks something up on one side, carries it across, and releases it on the other. is vastly reduced [2], [11].

If the rate of particle entry is low enough that the arterial wall’s endogenous clearance mechanisms—macrophage-mediated phagocytosis and HDL-mediated reverse CholesteroltransportDer reverse Cholesterintransport ist der Prozess, bei dem Cholesterin aus Geweben, einschließlich der Arterienwände, abtransportiert und zur Entsorgung zur Leber zurückgebracht wird. HDL-Partikel übernehmen dabei den Transport.—can remove particles before pro-inflammatory modification, the inflammatory cascade is never initiated [1], [12]. This is the mechanistic basis for a biological “no-effect” threshold for ApoB concentration, below which the probability of initiating a lesion approaches zero [7].

The Quantitative Relationship of Cumulative Exposure: Plaque-Years

Clinical risk of ASCVD reflects not instantaneous LDL-C but the integral of exposure over time, a concept now formalized as “cumulative LDL exposure” or “Plaque-JahrePlaque-years is a measure of cumulative lifetime exposure to LDL cholesterol, calculated as the integral of LDL-C concentration over time (approximated as LDL-C × age), used to quantify the total atherogenic burden an artery wall has experienced. Research has identified heuristic thresholds—around 5,000 for low risk and above 14,000 for very high risk—that correspond to progressively greater prob…” [13], [14]. Under this framework, atherosclerosis is a disease of gradual substrate accumulation, and the time to a clinical event is determined by how quickly an individual crosses a personal plaque thresholdThe plaque threshold is the individual-specific cumulative level of atherogenic lipoprotein exposure at which enough lesion burden has accumulated to produce a clinically meaningful cardiovascular event such as a heart attack or stroke. Risk factors such as hypertension, diabetes, and smoking effectively lower this threshold, meaning events occur at a smaller cumulative exposure, while a metaboli… [13]. Domanski and colleagues formally demonstrated in a pooled analysis of 4,958 participants from ARICARIC, die Atherosclerosis Risk in Communities-Studie, begleitet seit den späten 1980er Jahren Tausende amerikanische Erwachsene., CARDIACARDIA has followed young adults from their twenties into later life, tracking fitness, cholesterol, blood pressure, and what eventually happened to them., MESAMESA, the Multi-Ethnic Study of Atherosclerosis, followed thousands of adults with no known heart disease, scanning their arteries and tracking outcomes., and the Framingham Offspring Study that the cumulative burden of LDL-C exposure, the time course of that exposure, and the slope of LDL-C change over time each independently predicted incident cardiovascular events [14].

Defining the Plaque-Year Thresholds

Analysis of epidemiologic and Mendelsche RandomisierungDie Mendelsche Randomisierung ist eine intelligente Forschungsmethode, die die Gene, mit denen Menschen geboren wurden, als natürliches Experiment nutzt. data permits tentative quantification of cumulative-exposure thresholds [13], [15]. Published thresholds remain approximate and cohort-dependent rather than formally validated across populations, and the values below are best regarded as heuristic estimates drawn from long-term cohort and Mendelian RandomisierungRandomisierung ist der Prozess, bei dem Versuchsteilnehmer nach dem Zufallsprinzip Behandlungs- oder Kontrollgruppen zugeteilt werden, wodurch sichergestellt wird, dass bekannte und unbekannte Stöfaktoren gleichmäßig verteilt sind; wenn die Randomisierung fehlschlägt – was Prüfer im Fall von PREDIMED feststellten –, können sich die Gruppen auf eine Weise unterscheiden, die den scheinbaren Behandlungseffekt verzerrt. data [13]–[15].

Risk Metric (Men)	Approx. Cumulative LDL Exposure (g·yr/dL)	Lifetime Major Event Risk (approx.)
Low-Risk Threshold	~ 5,000	< 10% probability of event [13], [14]
Intermediate Threshold	~ 8,000	Approximate median age for non-zero CAC (~age 55–60) [13], [16]
High-Risk Threshold	~ 11,000	>20% probability of event [13], [14]
Very High-Risk Threshold	~ 14,000	Approximate median age for CAC ≥ 100 [13], [16]

Note: Thresholds for women are generally higher (estimated by roughly 20–30% at comparable risk strata), consistent with the observed later-life onset of ASCVD in women and premenopausal attenuation of LDL transcytosis and arterial-wall biology [13].

Influence of Secondary Risk Factors on the Retention Threshold

Cumulative LDL exposure required to initiate events is not static; it is modulated by the biological environment of the ArterieEine Arterie ist ein Blutgefäß, das Blut vom Herzen weg in den Rest des Körpers transportiert. [13]. BluthochdruckBluthochdruck ist der medizinische Begriff für hohe Blutdruckwerte., DiabetesDiabetes ist eine Erkrankung, bei der der Blutzucker zu hoch bleibt, entweder weil der Körper zu wenig Insulin produziert oder weil er auf das produzierte Insulin nicht mehr reagiert., und RauchenRauchen schädigt die Innenauskleidung der Blutgefäße, erhöht den Blutdruck, lässt das Blut leichter gerinnen und beschleunigt das Plaque-Wachstum. effectively lower the threshold by increasing particle retention or accelerating inflammatory response to retained lipids [2], [17].

• Hypertension: Erhöht BlutdruckBlutdruck ist die Kraft, mit der das Blut gegen Ihre Arterienwände drückt. Er wird als zwei Zahlen geschrieben, wie 120/80. Die obere Zahl ist der Druck, wenn sich Ihr Herz zusammenzieht, die untere, wenn es sich entspannt. increases LDL transcytosis across the endothelium and promotes synthesis of proteoglycans with higher ApoB affinity [7]. Shear stress on existing PlackenPlaque ist die Ansammlung von Cholesterin, Immunzellen, Narbengewebe und Kalzium in einer Arterienwand. raises rupture likelihood [13].
• Type 2 diabetes / InsulinresistenzUnter Insulinresistenz versteht man, dass Ihre Zellen nicht mehr richtig auf Insulin reagieren, sodass Ihre Bauchspeicheldrüse immer mehr davon ausschütten muss, um dieselbe Aufgabe zu erfüllen.: Chronic dysglycemia and hyperinsulinemia injure the arterial wall, promote adverse remodeling, and narrow the coronary LumenDas Lumen ist der offene Kanal innerhalb eines Blutgefäßes, in dem tatsächlich Blut fließt., so even small plaques become hemodynamically significant and thrombi more likely to be occlusive [14].
• Smoking: Tobacco exposure causes direct endothelial damage and oxidativer StressOxidative stress is an imbalance between damaging reactive molecules and the body's ability to neutralize them., accelerating intimal lipoprotein modification [2].
• Androgen abuse: In young male anabolic-androgenic steroid users, PlaquevolumenPlaque-Volumen ist die gesamte physische Menge an Plaque in einem Arterienabschnitt, gemessen in Kubikmillimetern. und Koronarer Kalzium-ScoreKoronare Arterienverkalkung ist ein Maß für verkalkte Plaqueablagerungen in den Wänden der Herzkranzgefäße, quantifiziert durch ein CT und ausgedrückt als Agatston-Score; höhere Werte weisen auf eine größere kumulative Plaque-Last hin und sagen zukünftige kardiovaskuläre Ereignisse voraus. scores correlate strongly with lifetime exposure, consistent with an independent acceleration of atherogenesis [18].

For a metabolically healthy individual with controlled blood pressure and no inflammatory comorbidity, the arterial wall can tolerate a higher cumulative burden before clinical disease manifests [13]. Under the zero-risk hypothesisThe zero-risk hypothesis proposes that atherosclerosis is not an inevitable consequence of aging but a substrate-dependent disease that requires sustained exposure to ApoB-containing lipoproteins to initiate; if lifelong circulating ApoB and LDL-C are kept near newborn baseline levels (roughly 10–20 mg/dL), the probability of initiating any atherosclerotic lesion approaches zero., maintaining LDL-C ≈ 15 mg/dL across an 80-year lifespan yields only ~1,200 g·yr/dL of kumulative ExpositionKumulative Exposition ist die Gesamtmenge an schädlichen Cholesterinpartikeln, denen Ihre Arterien im Laufe Ihres gesamten Lebens ausgesetzt waren – wie hoch, multipliziert mit der Dauer.—well below the ~5,000 g·yr/dL heuristic low-risk threshold and roughly an order of magnitude below thresholds associated with clinically meaningful event probabilities [13].

Genetic Null Models: Experiments of Nature

The most rigorous test of whether atherosclerosis can be eliminated lies in human genetic models of lifelong ultra-low ApoB exposure [2], [3]. These “experiments of nature” provide the strongest available evidence that, in the near-absence of atherogene PartikelAtherogene Partikel sind die ApoB-haltigen Lipoproteine – einschließlich LDL, IDL, VLDL und Lipoprotein(a) –, die in die Arterienwand eindringen und dort zurückgehalten werden können, um das Plaque-Wachstum einzuleiten und aufrechtzuerhalten; der Artikel verwendet den Begriff, um zu beschreiben, was wesentlich und nachhaltig gesenkt werden muss, um eine Plaque-Rückbildung zu erreichen., disease initiation is profoundly attenuated [19], [20]. Case-report numbers remain small and autopsy data are limited, so claims of “complete” absence should be interpreted as “markedly reduced burden beyond what is plausibly attributable to chance alone” rather than mathematically zero.

Abetalipoproteinemia (ABL) and MTTP Deficiency

Abetalipoproteinemia is an autosomal recessive disorder caused by biallelic loss-of-function mutations in MTTP, which is essential for assembly and secretion of ApoB-containing lipoproteins in the liver and intestine [19], [21]. Affected individuals have near-total absence of ApoB-containing lipoproteins in circulation; GesamtcholesterinDas Gesamtcholesterin fasst das Cholesterin in all Ihren Partikeln zusammen, sowohl schädliche als auch hilfreiche. is typically < 30 mg/dL and LDL-C < 5 mg/dL (often undetectable) [19].

Despite severe non-cardiac pathology (fat malabsorption, acanthocytosis, spinocerebellar degeneration, retinitis pigmentosa), clinical and limited autopsy evidence indicate a striking paucity of atherosclerotic lesions in ABL patients [19], [21]. KardiomyopathieCardiomyopathy is disease of the heart muscle itself, rather than of the arteries feeding it. and arrhythmias, when they occur, are attributed predominantly to fat-soluble vitamin deficiency (vitamin E) rather than IschämieIschämie liegt vor, wenn ein Gewebe nicht genügend Blut und Sauerstoff für die Anforderungen erhält, die an es gestellt werden. [19]. ABL thus functions as the closest available human null model for ApoB-driven atherosclerosis.

Familial Hypobetalipoproteinemia (FHBL)

FHBL results from heterozygous or biallelic APOB mutations producing truncated, secretion-incompetent ProteineProtein ist der Nährstoff, den Ihr Körper zum Aufbau und zur Reparatur von Muskeln und Gewebe verwendet. [22].

• Heterozygous FHBL: LDL-C typically 20–50 mg/dL, with markedly reduced lifetime ASCVD risk [22], [23].
• Homozygous / komplex-heterozygotCompound heterozygous describes a genetic state in which an individual inherits two different pathogenic mutations in the same gene—one from each parent—rather than two copies of the identical mutation; in HoFH, compound heterozygosity for two distinct LDLR mutations still abolishes or severely impairs LDL receptor function and produces the full HoFH phenotype. FHBL: LDL-C often < 10 mg/dL; phenotype resembles ABL and exhibits similarly marked protection against atherosclerotic disease on imaging and in available autopsy reports [22], [23].

Genetic Disorder	Mechanismus	LDL-C (mg/dL)	ASCVD Phenotype
Abetalipoproteinemia	MTTP LOF; no particle assembly	< 5	Markedly reduced / absent plaque [19]
Homozygous FHBL	APOB LOF; truncated proteins	< 10	Markedly reduced / absent plaque [22], [23]
PCSK9PCSK9 ist ein von der Leber produziertes Protein, das die Andockstellen zerstört, die Ihre Leber nutzt, um Cholesterin aus Ihrem Blut zu entfernen. LOF (compound het.)	Enhanced LDLRLDLR ist das Gen, das den LDL-Rezeptor bildet, die Andockstelle, die Ihre Leber nutzt, um Cholesterinteilchen aus dem Blutkreislauf zu ziehen. recycling; rapid LDL clearance	~ 14–15	Healthy phenotype; no documented ASCVD in index case [24]
ANGPTL3ANGPTL3 ist ein Protein, das den Abbau von Triglycerid-reichen Partikeln im Blut verlangsamt. Deficiency	Increased LPL/EL activity; low TG and LDL	~ 30–40	Markedly reduced CAD (~34–41% lower odds) [25], [26]

PCSK9 and ANGPTL3: The “Healthy” Ultra-Low Phenotype

Unlike ABL, which carries severe non-cardiac morbidity, loss-of-function variants in PCSK9 and ANGPTL3 produce ultra-low LDL-C without fat malabsorption or hepatic steatosis [3], [27]. The first reported compound heterozygous PCSK9 LOF individual, a healthy fertile African American woman described by Zhao and colleagues, had an LDL-C of approximately 14 mg/dL (0.36 mmol/L) and was clinically unremarkable, demonstrating that lifelong near-absence of circulating PCSK9 is compatible with normal human physiology [24]. In the Atherosclerosis Risk in Communities (ARIC) cohort, heterozygous PCSK9 LOF variants (PCSK9 Y142X and C679X) were associated with a 28% lower LDL-C and an 88% reduction in koronare HerzkrankheitDie koronare Herzkrankheit ist die Verengung oder Verstopfung der Arterien, die den Herzmuskel mit Blut versorgen, verursacht durch die Anlagerung von atherosklerotischer Plaque; sie ist weltweit die häufigste Ursache für Herzinfarkt und Herztod. incidence over approximately 15 years in Black participants, with a more modest ~47% reduction tied to PCSK9 R46L carriers in White participants [28]. Extended over a lifetime of exposure, the risk reduction approaches the near-complete protection observed in ABL and homozygous FHBL [2].

ANGPTL3 deficiency produces “combined hypolipidemia” with low LDL-C, HDL-C, and TriglycerideTriglyceride sind die Hauptform von Fett in Ihrem Blut und in den Fettspeichern Ihres Körpers. [27]. In Stitziel’s 2017 analysis, three compound-heterozygous individuals had zero coronary plaque on CT angiography versus a mean 39% PlaquebelastungPlaque-Last ist die Gesamtmenge an Plaque in Ihren Arterien, und zwar überall – nicht nur an der schlimmsten Einzelstelle. in matched relatives; heterozygous LOF carriers exhibited approximately 34% lower odds of Koronare HerzkrankheitKoronare Herzkrankheit ist eine Plaque-Ansammlung in den Arterien, die den Herzmuskel versorgen. (OR 0.66; 95% CI 0.44–0.98) [25]. Dewey and colleagues replicated this signal in 58,335 DiscovEHR participants, reporting a 41% lower odds of CAD (OR 0.59; 95% CI 0.41–0.85; p = 0.004) [26]. Critically, quantitative imaging confirms that ANGPTL3 LOF carriers do not have increased hepatic fat, distinguishing this pathway as a favorable target for long-term pharmacological mimicry [27].

Pharmacologic Evidence: The “Lower Is Better” Paradigm

Genetic models speak to lifelong exposure; pharmacologic trials test the effect of lowering LDL-C later in life, typically in individuals with existing subclinical or clinical disease [2].

Meta-Regression and the Linearity of Benefit

Data from the Cholesterol Treatment Trialists (CTT) Collaboration and subsequent non-statin trials (EzetimibEzetimib ist eine Tablette, die die Aufnahme von Cholesterin im Darm blockiert., PCSK9-HemmerEin PCSK9-Hemmer ist ein Medikament, das dieses cholesterinabbauende Protein blockiert, wodurch mehr Andockstellen frei bleiben, um Partikel aus dem Blut zu entfernen.) demonstrate a remarkably consistent Dosis-Wirkungs-BeziehungEine Dosis-Wirkungs-Beziehung bedeutet, dass eine größere Menge von etwas in einem konsistenten Gradienten eine stärkere Wirkung hervorruft.: every 1 mmol/L (38.7 mg/dL) reduction in LDL-C corresponds to approximately a 22% reduction in major vascular events per year of treatment, with the relationship remaining linear even at the lowest achieved levels examined [29], [30]. This relationship is effectively agnostic to the mechanism by which LDL-C is lowered [15], [31].

Klinische StudieEine klinische Studie ist eine Untersuchung, bei der Forscher einer Gruppe eine Behandlung und einer anderen Gruppe ein Placebo oder eine Standardbehandlung verabreichen und dann die Ergebnisse vergleichen. / Analysis	Achieved LDL-C (mg/dL)	Wichtigste Erkenntnis
CTT Meta-analysisEine Meta-Analyse fasst die Ergebnisse vieler einzelner Studien statistisch zu einer Gesamtschätzung zusammen.	Range 60–180	~22% RR reduction per 1 mmol/L (38.7 mg/dL) [29]
IMPROVE-ITIMPROVE-IT added ezetimibe to a statin after a heart attack, testing whether lowering LDL by a non-statin mechanism would help. (ezetimibe + simvastatin)	53.7 vs 69.5 (TWA)	HR 0.936 (0.89–0.99) for primary endpoint; benefit beyond StatinEin Statin verlangsamt das Enzym, das Ihre Leber zur Bildung von Cholesterin nutzt. Ihre Leber reagiert darauf, indem sie mehr Cholesterin aus Ihrem Blut zieht, und genau daraus ergibt sich der eigentliche Nutzen. alone [30]
FOURIERFOURIER untersuchte Evolocumab, einen PCSK9-Inhibitor, bei Patienten mit bereits bestehender kardiovaskulärer Erkrankung, die Statine einnahmen. (EvolocumabEvolocumab ist ein injizierbares Cholesterinmedikament aus der Familie der PCSK9-Hemmer, das normalerweise alle zwei bis vier Wochen verabreicht wird.)	Median ~30 (subgroup <20)	Linear benefit continued to LDL-C < 20 mg/dL [32], [33]
ODYSSEYODYSSEY OUTCOMES testete Alirocumab bei Patienten, die sich von einem kürzlichen Herzinfarkt erholten. ERGEBNISSE (AlirocumabAlirocumab, sold as Praluent, is an injectable antibody that blocks PCSK9, given every two to four weeks.)	~53 (48-wk mean)	HR 0.85 MACE; first mortality signal for PCSK9i (HR 0.85) [34]
PROLONG-ANG3 (solbinsiran)	Phase 2; sustained reduction	siRNA targeting ANGPTL3; durable ApoB and TG lowering [35]
CORALreef Lipids (enlicitide)	~60 on background statin	Oral PCSK9 inhibitor; Phase 3 LDL-C reduction [36]

The significance of these pharmacologic data lies in the “no-plateau” observation [32], [37]. Event reduction continues linearly even at achieved LDL-C below 20 mg/dL, suggesting that the biological drivers of atherosclerosis remain substrate-limited at the extremes of the lipid spectrum [2], [32].

Residual Disease versus New Initiation

A critical distinction must be drawn between primary and SekundärpräventionDie Sekundärprävention behandelt jemanden, der bereits einen Herzinfarkt, Schlaganfall oder Stent hatte, um den nächsten zu verhindern. [13]. Among trial participants achieving very low LDL-C, a meaningful fraction still experience events [38]. Dies RestrisikoResidual risk is the risk that remains after you have done the obvious things — cholesterol treated, blood pressure controlled, not smoking. is not a failure of the zero-risk hypothesis but rather the predictable consequence of the irreversible structural features of advanced plaque [2]. Once a lesion has developed a nekrotischer KernDer nekrotische Kern ist das tote, breiige Zentrum einer fortgeschrittenen Plaque, das aus Immunzellen besteht, die eingeschlossenes Cholesterin gefressen haben und dann an Ort und Stelle starben. and a thinned faserige KappeDie fibröse Kappe ist die zähe Gewebeschicht, die eine Plaque bedeckt und ihren fettigen Kern vom Blutstrom trennt., rupture can be triggered by local mechanical forces or systemic inflammation largely independent of current LDL-C [2], [39]. The zero-risk hypothesis concerns disease initiation, not terminal rupture of pre-existing plaque [1]. Were ultra-low lipoprotein levels maintained from birth, the substrate for acute events (mature, unstable plaqueAn unstable plaque is an atherosclerotic lesion with a thin fibrous cap, a large lipid-rich necrotic core, and active inflammation, making it prone to rupture even when it is not large enough to meaningfully restrict blood flow or cause symptoms.) would simply fail to form [2], [14].

Residual Risk Pathways: Can Inflammation or Lp(a) Initiate Disease Alone?

Falsifying the zero-risk hypothesis requires identifying a non-ApoB pathway capable of independently initiating atherosclerosis in the absence of atherogenic lipoproteins [5], [6].

Lipoprotein(a) and the Structural Necessity of ApoB

Lp(a) is a complex particle consisting of an LDL-like ApoB-100ApoB-100 ist die Full-Length-Form von Apolipoprotein B, die auf LDL, VLDL, IDL und Remnant-Lipoproteinen zu finden ist; ihre positiv geladenen Aminosäuredomänen binden ionisch an negativ geladene Proteoglykan-Seitenketten in der Arterienwand, wodurch das Partikel physisch in der Intima festgehalten und die Plaquebildung eingeleitet wird. core covalently bound to apolipoprotein(a) [40]. It is independently associated with ASCVD risk even when LDL-C is optimally controlled [5]. Mechanistically, Lp(a) is more atherogenic than LDL on a per-particle basis because of its propensity for matrix binding and its cargo of oxidized phospholipids (OxPLs), which drive robust inflammation [40], [41]. Critically, however, every Lp(a) particle requires an ApoB-100 scaffold; in ABL and homozygous FHBL, Lp(a) cannot be synthesized because ApoB secretion is absent [19], [22]. Thus, Lp(a) does not represent a non-ApoB initiation pathway but a quantitatively more atherogenic subclass of the ApoB-containing lipoprotein family.

Inflammation as a Potentiator, Not an Initiator

The role of inflammation (IL-6Interleukin-6 oder IL-6 ist ein Signalmolekül, das das Immunsystem nutzt, um eine entzündliche Botschaft im Körper zu verbreiten., IL-1β, hsCRP) in ASCVD is well established, and the CANTOS trialThe CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial was a landmark randomized controlled trial that tested whether canakinumab, an IL-1β inhibitor, could reduce cardiovascular events in high-risk patients with elevated hs-CRP after myocardial infarction; its positive results provided the first direct clinical evidence that inflammation is a causal, therapeutically modifiabl… demonstrated that canakinumab-mediated blockade of IL-1β reduces cardiovascular events without changing lipid levels [42]. Nevertheless, current consensus is that inflammation operates as a physiologic response of the arterial wall to retained lipoproteins rather than as an autonomous initiator [7]. In wild-type animal models, systemic inflammation does not generate atherosclerosis in the absence of hyperlipidemia [43]. Arterial-wall inflammation, monocyte recruitment, and foam-cell formation are downstream consequences of lipoprotein retention [1]. Chronic inflammatory diseases (e.g., rheumatoid arthritisRheumatoid arthritis is an autoimmune disease in which the immune system attacks the joints., SLE) lower the threshold for retention-driven lesion formation, but they do not initiate atherosclerosis where the ApoB substrate is absent [7].

Imaging the Ultra-Low End: Subclinical Evidence

Koronarkalk-MessungA non-contrast, ECG-gated CT scan that detects and quantifies calcified plaque in the coronary arteries; the resulting Agatston score reflects the extent of coronary calcification and serves as a direct, disease-based measure of atherosclerotic burden rather than a statistical estimate of risk., Intravaskulärer UltraschallDer Intravaskuläre Ultraschall, kurz IVUS, verwendet eine winzige Ultraschallsonde, die in eine Koronararterie eingeführt wird, um die Wand von innen zu fotografieren. (IVUS), optische KohärenztomographieDie optische Kohärenztomographie, kurz OCT, führt eine lichtbasierte Sonde in eine Koronararterie ein. Sie liefert etwa zehnmal detailgenauere Bilder als Ultraschall. (OCT), and Koronare CT-AngiographieDie Koronar-CT-Angiographie, kurz CCTA, ist eine CT-Untersuchung mit Kontrastmittel in den Venen, die detaillierte Bilder der Herzkranzgefäße liefert. (CCTA) provide complementary windows into the presence and composition of subclinical plaque at extreme lipid strata [16], [44].

The Power of Zero CAC

A CAC score of zero is a robust marker of low short-term event risk, but its interpretation is age-dependent [16], [45]. In younger populations (age < 45), zero CAC is common even among those with significant LDL exposure because VerkalkungVerkalkung tritt auf, wenn sich Kalzium in einer Plaque ablagert, wodurch diese teilweise hart und knöchern wird. is a late-stage stabilization marker [45]. Conversely, zero CAC in an elderly individual is uncommon and identifies exceptional resistance to atherogenesis, often associated with genetically low ApoB or favorable matrix biology [16], [46].

CAC Category	Agatston-EinheitenAgatston-Einheiten sind die standardisierten Bewertungseinheiten zur Quantifizierung von Koronarkalk in einem CT-Scan, berechnet aus der Dichte und der Fläche verkalkter Läsionen; ein Score von Null zeigt keine nachweisbare verkalkte Plaque an, während Scores von 300 oder mehr – die in der UK-Masters-Studie ausschließlich in der Athletengruppe gefunden wurden – eine starke Verkalkung widerspiegeln.	Klinische Bedeutung
Null	0	No detectable calcification; very low short-term ASCVD risk [16]
Mild	1–99	Early atherosclerotic burden; supports risk up-classification [16]
Mäßig	100–399	Significant plaque; 10-yr event risk typically exceeds 7.5% [16]
Schwerwiegend	≥ 400	Very high risk; often treated as ASCVD equivalent [16]

IVUS and the Threshold for Regression

Intravascular imaging trials consistently show that deep LDL-C lowering can reverse net plaque burden [47], [48]. Das ASTEROID-StudieEine bahnbrechende serielle IVUS-Studie aus dem Jahr 2006, in der Rosuvastatin 40 mg täglich über 24 Monate statistisch signifikante Reduktionen sowohl des prozentualen Atheromvolumens als auch des Gesamtatheromvolumens bewirkte, was den ersten großangelegten Beweis dafür lieferte, dass eine intensive Statintherapie Koronarplaque zurückbilden kann. achieved mean LDL-C of 60.8 mg/dL with RosuvastatinRosuvastatin, verkauft als Crestor, ist das wirksamste verfügbare Statin und verbleibt größtenteils in der Leber, anstatt sich im Körper zu verteilen. 40 mg and demonstrated regression of Atheromvolumen in ProzentDas prozentuale Atheromvolumen, oder PAV, ist der Anteil eines Arteriensegments, der von Plaque statt von einem offenen Kanal eingenommen wird. (PAV) across multiple imaging parameters [47]. SaturnSATURN verglich die beiden stärksten Statine direkt miteinander in Höchstdosis und maß dabei die koronare Plaque mittels intravaskulärem Ultraschall. corroborated regression at LDL-C in the 60–70 mg/dL range [48]. GLAGOVGLAGOV fügte der Statintherapie einen PCSK9-Inhibitor hinzu und maß die koronare Plaque vor und nach der Behandlung mittels intravaskulärem Ultraschall. extended the relationship into the PCSK9-inhibitor era, showing continuous linear regression with evolocumab down to LDL-C < 40 mg/dL, with no apparent plateau [49].

• Regression: Reduction in PAV is observed consistently when LDL-C falls below ~70 mg/dL, with the magnitude of regression scaling with the depth of LDL-C reduction [47]–[49].
• Stabilization: At ultra-low levels, plaques undergo beneficial remodeling; the lipid-rich core shrinks and the fibrous cap thickens and becomes collagen-rich, converting a “vulnerable” lesion into a structurally stable one [49], [50].

Under the zero-risk hypothesis, early-life maintenance of LDL-C ≈ 15 mg/dL would prevent formation of the lipid-rich core entirely; regression and stabilization become moot because there is no lesion to regress [2].

Temporal Considerations: Early-Life Exposure versus Adult Intervention

The cumulative-exposure framework emphasizes that the age at which LDL lowering begins matters as much as its intensity [13].

The Window of Opportunity

Ference and colleagues’ landmark 2012 Mendelian randomization analysis pooled nine SNPs across six LDL-regulating genes and found that each standard unit of genetically lower LDL-C produced approximately a three-fold greater proportional reduction in coronary heart disease than the same magnitude of late-life statin-induced LDL-C lowering [15]. Specifically, lifelong exposure to ~1 mmol/L lower LDL-C was associated with roughly a 54–55% reduction in CHD risk, versus approximately a 22% relatives RisikoDas relative Risiko vergleicht zwei Gruppen: Diese Gruppe hatte 30 Prozent weniger Herzinfarkte als jene Gruppe. reduction per mmol/L with statin therapy initiated in midlife [15], [29]. This discrepancy arises because early intervention prevents lesion initiation, whereas late intervention merely slows progression of already-mature plaques [2], [14].

For a metabolically healthy individual:

• Maintaining LDL-C ≈ 15 mg/dL lifelong: Prevents plaque initiation; lifetime risk approaches zero [2], [15].
• Reducing LDL-C to ≈ 15 mg/dL at age 40: Halts further progression, stabilizes existing subclinical plaque, and delays clinical events by an estimated 10–20 years depending on baseline plaque burden [13], [14].
• Reducing LDL-C to ≈ 15 mg/dL after a clinical event: Reduces recurrence risk by stabilizing vulnerable PlaquesEine vulnerable Plaque ist eine Plaque mit hohem Risiko des Aufreißens: eine dünne Kappe, ein großer fettiger Kern, aktive Entzündung und oft eine Ausbuchtung der Arterie nach außen.; does not eliminate residual risk arising from irreversible structural damage [34], [50].

The biological primacy of primary—and ideally primordial—prevention follows directly: maintaining physiologic lipoprotein levels from the earliest stages of life avoids the transition from subclinical to clinically dangerous burden [3].

Theoretical and Mechanistic Limits: Stochastic versus Zero Risk

Is the elimination of atherosclerosis absolute, or does a biological floor persist?

Stochastic Retention at Extreme Lows

Atherosclerosis initiation is fundamentally a probabilistic process [7]. Even at LDL-C ≈ 15 mg/dL, an ApoB particle could in principle enter the arterial wall, bind a proteoglycan, and undergo oxidation [7]. However, the probability of enough such particles being retained in a single focal region to trigger a self-perpetuating inflammatory response becomes vanishingly small at ultra-low concentrations [7], [9].

Arterial-wall biology incorporates multiple fail-safe mechanisms:

• Resident scavenging: Healthy intimal macrophages can clear small quantities of modified lipoprotein without becoming foam cells or secreting pro-inflammatory cytokines [1].
• HDLHDL oder Lipoprotein hoher Dichte ist das Partikel, das oft als "gutes Cholesterin" bezeichnet wird. Es nimmt Cholesterin aus dem Gewebe auf und transportiert es zurück zur Leber./ApoA-I efflux: HDL functions as a bidirectional lipid vector capable of removing excess cholesterol from the intima; at low ApoB influx, efflux capacity easily maintains homeostatic balance [8], [51].
• Matrix integrity: In the absence of sustained lipid retention, the intima remains thin and structurally intact, with preserved elastic FasernBallaststoffe sind der Teil pflanzlicher Nahrung, den der Körper nicht verdauen kann. Sie sind in Bohnen, Haferflocken, Gemüse, Obst und Vollkornprodukten enthalten. and minimal proteoglycan expansion [9].

At the zero-risk target of LDL-C ≈ 15 mg/dL, the probability of plaque initiation may not be mathematically zero but is effectively zero in biological and clinical terms: accumulation would never reach the critical mass required for disease within a human lifespan [2], [14]. Das Horus-StudieThe Horus study used CT imaging to assess 137 mummies from four ancient populations spanning more than 4,000 years, finding probable or definite atherosclerosis in 34 percent, demonstrating that arterial disease predates modern industrialized diet and lifestyle. of 137 mummies across 4,000 years of history—including Tsimane-like pre-industrial and ancient peoples—documents vascular calcification in every era examined, but notably, pre-industrial populations with very low LDL-C (e.g., the contemporary TsimaneThe Tsimane are an indigenous forager-horticulturalist population of the Bolivian Amazon whose traditional lifestyle—characterized by high physical activity and low average LDL cholesterol of around 91 mg/dL—is associated with markedly low rates of coronary calcification, with 85 percent of adults over 40 showing no detectable coronary calcium., with mean LDL-C ~91 mg/dL and the lowest prevalence of coronary atherosclerosis measured in any human population) exhibit only low rates of subclinical CAC even in the elderly [52], [53]. Extrapolating to lifelong LDL-C of 15 mg/dL implies burden far below even this baseline.

Synthesis of the Zero-Risk Hypothesis Outcomes

Three hypothesis variants can be tested against the evidence reviewed above.

Strong Form: Zero-Risk Hypothesis

Lifelong LDL-C ≈ 15 mg/dL in a metabolically healthy individual produces effectively zero probability of clinically meaningful atherosclerosis. Evaluation: supported by human genetic null models (ABL, homozygous FHBL) where atherosclerotic burden is markedly reduced or absent [19], [22], by the physiologic newborn LDL-C baseline, and by the consistent absence of events in ultra-low-exposure genetic cohorts [2], [24].

Weak Form: Asymptotic Hypothesis

Risk approaches zero but never fully reaches it because of stochastic retention or non-ApoB pathways. Evaluation: supported by the fundamentally probabilistic nature of particle–wall interactions [7]. Extreme age or severe systemic inflammation could, in principle, cause minimal intimal changes, though such lesions would likely remain subclinical across the human lifespan [7].

Null Hypothesis

Atherosclerosis still occurs at meaningful rates independent of LDL at very low levels. Evaluation: refuted for the ideal phenotype [2], [15]. Residual risk observed in treated secondary-prevention populations is consistently attributable to pre-existing plaque and to non-LDL ApoB-haltige PartikelLipoproteine – einschließlich LDL, IDL, VLDL und deren Remnants –, die jeweils ein Molekül Apolipoprotein B an ihrer Oberfläche tragen; die Partikelanzahl (und nicht allein die Cholesterinmasse) ist ein Haupttreiber der Atherosklerose, da jedes Partikel in der Arterienwand retiniert werden kann. (triglyceride-rich remnants and Lp(a)) rather than to a non-ApoB mechanism of initiation [5], [40].

Clinical Phenotype	Expected Plaque Burden	Event Risk Probability
Ideal phenotype (lifelong LDL-C ~15 mg/dL)	Zero / undetectable	Effectively zero [15]
Healthy adult (lifelong LDL-C ~70 mg/dL)	Minimal / aging-related	Low (~5–10%) [14]
Western adult (lifelong LDL-C ~130 mg/dL)	Progressive / mature	High [2], [14]
Secondary prevention (achieved LDL-C ~15 mg/dL)	Stable / calcified	Significant residual [34]

Conclusion: Redefining the Threshold of Human Health

The evaluation of the zero-risk hypothesis supports the view that atherosclerosis is a substrate-dependent disease requiring a minimum lifelong cumulative exposure to ApoB-containing lipoproteins to initiate [2], [14]. The quantitative relationship between cumulative exposure and plaque formation implies that maintaining LDL-C in the 10–20 mg/dL range from birth delays disease initiation beyond the biological limits of human longevity [13], [15].

Genetic models (abetalipoproteinemia, homozygous FHBL, and healthy ultra-low phenotypes from PCSK9 and ANGPTL3 loss of function) demonstrate that such low levels are both safe and compatible with a marked reduction—and in some cases apparent absence—of atherosclerotic plaque, acknowledging that case numbers remain limited [19], [22], [24], [25]. While residual risks driven by Lp(a), remnants, and inflammation persist in patients with mature disease, these factors are insufficient to initiate atherogenesis in the near-total absence of ApoB particles [2], [40].

The implication for preventive cardiology is substantial [3]. Rather than managing risk as an inevitable consequence of aging, the proper objective is PrimärpräventionDie Primordialprävention ist eine Strategie, die darauf abzielt, die Entstehung kardiovaskulärer Risikofaktoren von vornherein zu verhindern – statt Risikofaktoren oder bereits bestehende Erkrankungen zu behandeln –, indem atherogene Belastungen von Geburt an oder in der frühen Kindheit gegen Null gehalten werden. Sie unterscheidet sich von der Primärprävention, die auf Personen abzielt, die bereits Risikofaktoren, aber noch keine klinische Erkrankung haben.: maintaining physiologic lipoprotein levels throughout the earliest stages of life to eliminate the substrate for atherogenesis [2], [15]. This paradigm suggests that heart disease—the leading cause of death worldwide—is biologically eradicable if ApoB particle retention is prevented throughout the human lifespan [2], [14].

Referenzen

1. J. Borén, M. J. Chapman, R. M. Krauss, C. J. Packard, J. F. Bentzon, C. J. Binder, M. J. Daemen, L. L. Demer, R. A. Hegele, S. J. Nicholls, B. G. Nordestgaard, G. F. Watts, E. Bruckert, S. Fazio, B. A. Ference, I. Graham, J. D. Horton, U. Landmesser, U. Laufs, L. Masana, G. Pasterkamp, F. J. Raal, K. K. Ray, H. Schunkert, M.-R. Taskinen, B. van de Sluis, O. Wiklund, L. Tokgözoğlu, A. L. Catapano, and H. N. Ginsberg, “Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights—a consensus statement from the European Atherosclerosis Society Consensus Panel,” Eur. Heart J., vol. 41, no. 24, pp. 2313–2330, Jun. 2020, doi: 10.1093/eurheartj/ehz962.
2. B. A. Ference, H. N. Ginsberg, I. Graham, K. K. Ray, C. J. Packard, E. Bruckert, R. A. Hegele, R. M. Krauss, F. J. Raal, H. Schunkert, G. F. Watts, J. Borén, S. Fazio, J. D. Horton, L. Masana, S. J. Nicholls, B. G. Nordestgaard, B. van de Sluis, M.-R. Taskinen, L. Tokgözoğlu, U. Landmesser, U. Laufs, O. Wiklund, J. K. Stock, M. J. Chapman, and A. L. Catapano, “Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies,” Eur. Heart J., vol. 38, no. 32, pp. 2459–2472, Aug. 2017, doi: 10.1093/eurheartj/ehx144.
3. A. L. Catapano, I. Graham, G. De Backer, O. Wiklund, M. J. Chapman, H. Drexel, A. W. Hoes, C. S. Jennings, U. Landmesser, T. R. Pedersen, Ž. Reiner, G. Riccardi, M.-R. Taskinen, L. Tokgözoğlu, W. M. M. Verschuren, P. Vlachopoulos, D. A. Wood, and J. L. Zamorano, “2016 ESC/EAS guidelines for the management of dyslipidaemias,” Eur. Heart J., vol. 37, no. 39, pp. 2999–3058, Oct. 2016, doi: 10.1093/eurheartj/ehw272.
4. J. H. O’Keefe, L. Cordain, W. H. Harris, R. M. Moe, and R. Vogel, “Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal,” J. Am. Coll. Cardiol., vol. 43, no. 11, pp. 2142–2146, Jun. 2004, doi: 10.1016/j.jacc.2004.03.046.
5. B. G. Nordestgaard, M. J. Chapman, K. Ray, J. Borén, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M. R. Taskinen, L. Tokgözoğlu, and A. Tybjærg-Hansen, “Lipoprotein(a) as a cardiovascular risk factor: current status,” Eur. Heart J., vol. 31, no. 23, pp. 2844–2853, Dec. 2010, doi: 10.1093/eurheartj/ehq386.
6. B. G. Nordestgaard and A. Varbo, “Triglycerides and cardiovascular disease,” Lancet, vol. 384, no. 9943, pp. 626–635, Aug. 2014, doi: 10.1016/S0140-6736(14)61177-6.
7. I. Tabas, K. J. Williams, and J. Borén, “Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications,” Circulation, vol. 116, no. 16, pp. 1832–1844, Oct. 2007, doi: 10.1161/CIRCULATIONAHA.106.676890.
8. P. Libby, “The changing landscape of atherosclerosis,” Nature, vol. 592, no. 7855, pp. 524–533, Apr. 2021, doi: 10.1038/s41586-021-03392-8.
9. D. C. Schwenke and T. E. Carew, “Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries,” Arteriosclerosis, vol. 9, no. 6, pp. 908–918, Nov./Dec. 1989, doi: 10.1161/01.atv.9.6.908.
10. R. Ross, “Atherosclerosis—an inflammatory disease,” N. Engl. J. Med., vol. 340, no. 2, pp. 115–126, Jan. 1999, doi: 10.1056/NEJM199901143400207.
11. F. Mach, C. Baigent, A. L. Catapano, K. C. Koskinas, M. Casula, L. Badimon, M. J. Chapman, G. G. De Backer, V. Delgado, B. A. Ference, I. M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T. R. Pedersen, G. Riccardi, D. J. Richter, M. S. Sabatine, M.-R. Taskinen, L. Tokgözoğlu, and O. Wiklund, “2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk,” Eur. Heart J., vol. 41, no. 1, pp. 111–188, Jan. 2020, doi: 10.1093/eurheartj/ehz455.
12. A. R. Tall and L. Yvan-Charvet, “Cholesterol, inflammation and innate immunity,” Nat. Rev. Immunol., vol. 15, no. 2, pp. 104–116, Feb. 2015, doi: 10.1038/nri3793.
13. J. Brandts and K. K. Ray, “The LDL cumulative exposure hypothesis: evidence and practical applications,” Nat. Rev. Cardiol., vol. 21, no. 9, pp. 600–608, Sep. 2024, doi: 10.1038/s41569-024-01039-5.
14. M. J. Domanski, X. Tian, C. O. Wu, J. P. Reis, A. K. Dey, Y. Gu, L. Zhao, S. Bae, K. Liu, A. A. Hasan, D. Zimrin, M. R. Farkouh, A. R. Hong, D. M. Lloyd-Jones, and V. Fuster, “Time course of LDL cholesterol exposure and cardiovascular disease event risk,” J. Am. Coll. Cardiol., vol. 76, no. 13, pp. 1507–1516, Sep. 2020, doi: 10.1016/j.jacc.2020.07.059.
15. B. A. Ference, W. Yoo, I. Alesh, N. Mahajan, K. K. Mirowska, A. Mewada, J. Kahn, L. Afonso, K. A. Williams, and J. M. Flack, “Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis,” J. Am. Coll. Cardiol., vol. 60, no. 25, pp. 2631–2639, Dec. 2012, doi: 10.1016/j.jacc.2012.09.017.
16. R. Detrano, A. D. Guerci, J. J. Carr, D. E. Bild, G. Burke, A. R. Folsom, K. Liu, S. Shea, M. Szklo, D. A. Bluemke, D. H. O’Leary, R. Tracy, K. Watson, N. D. Wong, and R. A. Kronmal, “Coronary calcium as a predictor of coronary events in four racial or ethnic groups,” N. Engl. J. Med., vol. 358, no. 13, pp. 1336–1345, Mar. 2008, doi: 10.1056/NEJMoa072100.
17. S. Yusuf, S. Hawken, S. Ôunpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, and L. Lisheng, “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” Lancet, vol. 364, no. 9438, pp. 937–952, Sep. 2004, doi: 10.1016/S0140-6736(04)17018-9.
18. A. L. Baggish, R. B. Weiner, G. Kanayama, J. I. Hudson, M. H. Picard, A. M. Hutter Jr., and H. G. Pope Jr., “Cardiovascular toxicity of illicit anabolic-androgenic steroid use,” Circulation, vol. 135, no. 21, pp. 1991–2002, May 2017, doi: 10.1161/CIRCULATIONAHA.116.026945.
19. A. J. Hooper, B. A. Burnett, and J. R. Burnett, “Abetalipoproteinemia,” GeneReviews® [Internet], Univ. of Washington, Seattle, updated Jul. 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK532447/.
20. J. C. Cohen, E. Boerwinkle, T. H. Mosley Jr., and H. H. Hobbs, “Sequence variations in PCSK9, low LDL, and protection against coronary heart disease,” N. Engl. J. Med., vol. 354, no. 12, pp. 1264–1272, Mar. 2006, doi: 10.1056/NEJMoa054013.
21. M. M. Berriot-Varoqueaux, L. P. Aggerbeck, M. Samson-Bouma, and J. R. Wetterau, “The role of the microsomal triglyceride transfer protein in abetalipoproteinemia,” Annu. Rev. Nutr., vol. 20, pp. 663–697, 2000, doi: 10.1146/annurev.nutr.20.1.663.
22. S. G. Young and A. J. Hooper, “APOB-related familial hypobetalipoproteinemia,” GeneReviews® [Internet], Univ. of Washington, Seattle, updated Feb. 2021. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK570370/.
23. L. Tarugi, E. Averna, E. Di Leo, A. Cefalù, D. Noto, S. Magnolo, M. Cattin, S. Bertolini, and M. Calandra, “Molecular diagnosis of hypobetalipoproteinemia: an ENID review,” Atherosclerosis, vol. 195, no. 2, pp. e19–e27, Dec. 2007, doi: 10.1016/j.atherosclerosis.2007.05.003.
24. Z. Zhao, Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs, “Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote,” Am. J. Hum. Genet., vol. 79, no. 3, pp. 514–523, Sep. 2006, doi: 10.1086/507488.
25. N. O. Stitziel, A. V. Khera, X. Wang, A. J. Bierhals, A. C. Vourakis, A. E. Sperry, P. Natarajan, D. Klarin, C. A. Emdin, S. M. Zekavat, A. Nomura, J. Erdmann, H. Schunkert, N. J. Samani, W. E. Kraus, S. H. Shah, B. Yu, E. Boerwinkle, D. J. Rader, N. Gupta, P. M. Frossard, A. Rasheed, J. Danesh, E. S. Lander, S. Gabriel, D. Saleheen, K. Musunuru, and S. Kathiresan, “ANGPTL3 deficiency and protection against coronary artery disease,” J. Am. Coll. Cardiol., vol. 69, no. 16, pp. 2054–2063, Apr. 2017, doi: 10.1016/j.jacc.2017.02.030.
26. F. E. Dewey, V. Gusarova, R. L. Dunbar, C. O’Dushlaine, C. Schurmann, O. Gottesman, S. McCarthy, C. V. Van Hout, S. Bruse, H. M. Dansky, J. B. Leader, M. F. Murray, M. D. Ritchie, H. L. Kirchner, D. H. Ledbetter, J. Penn, A. Lopez, I. B. Borecki, J. D. Overton, J. G. Reid, D. J. Carey, A. J. Murphy, G. D. Yancopoulos, A. Baras, J. Gromada, and A. R. Shuldiner, “Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease,” N. Engl. J. Med., vol. 377, no. 3, pp. 211–221, Jul. 2017, doi: 10.1056/NEJMoa1612790.
27. K. Musunuru, J. P. Pirruccello, R. Do, G. M. Peloso, C. Guiducci, C. Sougnez, K. V. Garimella, S. Fisher, J. Abreu, A. J. Barry, T. Fennell, E. Banks, L. Ambrogio, K. Cibulskis, A. Kernytsky, E. Gonzalez, N. Rudzicz, J. C. Engert, M. A. DePristo, M. J. Daly, J. C. Cohen, H. H. Hobbs, D. Altshuler, G. Schonfeld, S. B. Gabriel, P. Yue, and S. Kathiresan, “Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia,” N. Engl. J. Med., vol. 363, no. 23, pp. 2220–2227, Dec. 2010, doi: 10.1056/NEJMoa1002926.
28. C. Baigent, L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, and R. Collins (Cholesterol Treatment Trialists’ Collaboration), “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials,” Lancet, vol. 376, no. 9753, pp. 1670–1681, Nov. 2010, doi: 10.1016/S0140-6736(10)61350-5.
29. Cholesterol Treatment Trialists’ (CTT) Collaboration, “Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials,” Lancet, vol. 385, no. 9976, pp. 1397–1405, Apr. 2015, doi: 10.1016/S0140-6736(14)61368-4.
30. C. P. Cannon, M. A. Blazing, R. P. Giugliano, A. McCagg, J. A. White, P. Theroux, H. Darius, B. S. Lewis, T. O. Ophuis, J. W. Jukema, G. M. De Ferrari, W. Ruzyllo, P. De Lucca, K. Im, E. A. Bohula, C. Reist, S. D. Wiviott, A. M. Tershakovec, T. A. Musliner, E. Braunwald, and R. M. Califf, “Ezetimibe added to statin therapy after acute coronary syndromes,” N. Engl. J. Med., vol. 372, no. 25, pp. 2387–2397, Jun. 2015, doi: 10.1056/NEJMoa1410489.
31. J. Silverman, L. A. Ballantyne, D. A. Bhatt, S. D. Wiviott, M. S. Sabatine, and Cholesterol Treatment Trialists, “Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis,” JAMA, vol. 316, no. 12, pp. 1289–1297, Sep. 2016, doi: 10.1001/jama.2016.13985.
32. M. S. Sabatine, R. P. Giugliano, A. C. Keech, N. Honarpour, S. D. Wiviott, S. A. Murphy, J. F. Kuder, H. Wang, T. Liu, S. M. Wasserman, P. S. Sever, and T. R. Pedersen, “Evolocumab and clinical outcomes in patients with cardiovascular disease,” N. Engl. J. Med., vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664.
33. R. P. Giugliano, T. R. Pedersen, A. C. Keech, A. Park, S. D. Wiviott, S. A. Murphy, J. F. Kuder, H. Wang, T. Liu, J. Lopez, and M. S. Sabatine, “Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial,” Lancet, vol. 390, no. 10106, pp. 1962–1971, Oct. 2017, doi: 10.1016/S0140-6736(17)32290-0.
34. G. G. Schwartz, P. G. Steg, M. Szarek, D. L. Bhatt, V. A. Bittner, R. Diaz, J. M. Edelberg, S. G. Goodman, C. Hanotin, R. A. Harrington, J. W. Jukema, G. Lecorps, K. W. Mahaffey, A. Moryusef, R. Pordy, K. Quintero, M. T. Roe, W. J. Sasiela, J.-F. Tamby, P. Tricoci, H. D. White, A. M. Zeiher, and ODYSSEY OUTCOMES Committees and Investigators, “Alirocumab and cardiovascular outcomes after acute coronary syndrome,” N. Engl. J. Med., vol. 379, no. 22, pp. 2097–2107, Nov. 2018, doi: 10.1056/NEJMoa1801174.
35. C. M. Ballantyne, J. P. Kastelein, L. A. Leiter, S. J. Nicholls, and colleagues, “Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial,” Lancet, 2025 (advance online publication).
36. S. J. Nicholls, C. M. Ballantyne, and colleagues (CORALreef Lipids Investigators), “Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, in adults with hypercholesterolemia: the Phase 3 CORALreef Lipids trial,” N. Engl. J. Med., 2025 (publication pending).
37. M. Bhandari, S. M. Nissen, and colleagues, “How low can you go? New evidence supports no lower bound to low-density lipoprotein cholesterol level in secondary prevention,” Circulation, vol. 147, no. 19, pp. 1433–1435, May 2023, doi: 10.1161/CIRCULATIONAHA.123.064041.
38. P. M. Ridker, N. Mora, L. Rose, and JUPITER Trial Study Group, “Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents,” Eur. Heart J., vol. 37, no. 17, pp. 1373–1379, May 2016, doi: 10.1093/eurheartj/ehw046.
39. P. Libby, P. M. Ridker, and G. K. Hansson, “Progress and challenges in translating the biology of atherosclerosis,” Nature, vol. 473, no. 7347, pp. 317–325, May 2011, doi: 10.1038/nature10146.
40. S. Tsimikas, “A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies,” J. Am. Coll. Cardiol., vol. 69, no. 6, pp. 692–711, Feb. 2017, doi: 10.1016/j.jacc.2016.11.042.
41. S. Tsimikas, H.-K. Gordts, C. Nora, C. Yeang, and J. L. Witztum, “Statin therapy increases lipoprotein(a) levels,” Eur. Heart J., vol. 41, no. 24, pp. 2275–2284, Jun. 2020, doi: 10.1093/eurheartj/ehz310.
42. P. M. Ridker, B. M. Everett, T. Thuren, J. G. MacFadyen, W. H. Chang, C. Ballantyne, F. Fonseca, J. Nicolau, W. Koenig, S. D. Anker, J. J. P. Kastelein, J. H. Cornel, P. Pais, D. Pella, J. Genest, R. Cifkova, A. Lorenzatti, T. Forster, Z. Kobalava, L. Vida-Simiti, M. Flather, H. Shimokawa, H. Ogawa, M. Dellborg, P. R. F. Rossi, R. P. T. Troquay, P. Libby, R. J. Glynn, and CANTOS Trial Group, “Antiinflammatory therapy with canakinumab for atherosclerotic disease,” N. Engl. J. Med., vol. 377, no. 12, pp. 1119–1131, Sep. 2017, doi: 10.1056/NEJMoa1707914.
43. A. Daugherty, S. E. Tall, M. J. Daemen, E. Falk, E. M. Fisher, E. Garcia-Cardena, A. R. Lusis, A. P. Owens III, M. E. Rosenfeld, and I. Tabas, “Recommendation on design, execution, and reporting of animal atherosclerosis studies: a scientific statement from the American Heart Association,” Arterioscler. Thromb. Vasc. Biol., vol. 37, no. 9, pp. e131–e157, Sep. 2017, doi: 10.1161/ATV.0000000000000062.
44. M. J. Budoff, S. Achenbach, R. S. Blumenthal, J. J. Carr, J. G. Goldin, P. Greenland, A. D. Guerci, J. A. Lima, D. J. Rader, G. D. Rubin, L. J. Shaw, S. E. Wiegers, American Heart Association Committee on Cardiovascular Imaging and Intervention, American Heart Association Council on Cardiovascular Radiology and Intervention, American Heart Association Committee on Cardiac Imaging, “Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the AHA,” Circulation, vol. 114, no. 16, pp. 1761–1791, Oct. 2006, doi: 10.1161/CIRCULATIONAHA.106.178458.
45. H. S. Hecht, “Coronary artery calcium scanning: past, present, and future,” JACC Cardiovasc. Imaging, vol. 8, no. 5, pp. 579–596, May 2015, doi: 10.1016/j.jcmg.2015.02.006.
46. K. Nasir, M. B. Rivera, R. Blankstein, M. J. Blaha, A. D. Choi, R. S. Blumenthal, M. G. Silverman, A. Dardari, J. Berman, J. Yeboah, M. J. Budoff, J. J. Carr, and M. Cainzos-Achirica, “Implications of coronary artery calcium testing for primary prevention,” J. Am. Coll. Cardiol., vol. 66, no. 15, pp. 1657–1668, Oct. 2015, doi: 10.1016/j.jacc.2015.07.066.
47. S. E. Nissen, S. J. Nicholls, I. Sipahi, P. Libby, J. S. Raichlen, C. M. Ballantyne, J. Davignon, R. Erbel, J. C. Fruchart, J.-C. Tardif, P. Schoenhagen, T. Crowe, V. Cain, K. Wolski, M. Goormastic, and E. M. Tuzcu, “Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial,” JAMA, vol. 295, no. 13, pp. 1556–1565, Apr. 2006, doi: 10.1001/jama.295.13.jpc60002.
48. S. E. Nissen, S. J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochellière, C. S. Staniloae, K. Mavromatis, J. Saw, B. Hu, A. M. Lincoff, E. M. Tuzcu, and PERISCOPE Investigators, “Effect of rosuvastatin versus atorvastatin on progression of coronary atherosclerosis in patients with coronary artery disease (SATURN),” N. Engl. J. Med., vol. 365, no. 22, pp. 2078–2087, Dec. 2011, doi: 10.1056/NEJMoa1110874.
49. S. J. Nicholls, R. Puri, T. Anderson, C. M. Ballantyne, L. Cho, J. J. P. Kastelein, W. Koenig, R. Somaratne, H. Kassahun, J. Yang, S. M. Wasserman, R. Scott, I. Ungi, J. Podolec, A. O. Ophuis, J. H. Cornel, M. Borgman, D. M. Brennan, and S. E. Nissen, “Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial,” JAMA, vol. 316, no. 22, pp. 2373–2384, Dec. 2016, doi: 10.1001/jama.2016.16951.
50. A. V. Khera, E. S. Everett, M. G. Caulfield, F. E. Hantgan, J. Deasy, R. K. Scott, P. S. Sever, J. Barton, L. Heller, A. Nambi, and M. S. Sabatine, “Evolocumab, plaque regression, and clinical outcomes,” J. Am. Coll. Cardiol., vol. 75, no. 9, pp. 1037–1050, Mar. 2020, doi: 10.1016/j.jacc.2019.12.052.
51. D. J. Rader and G. K. Hovingh, “HDL and cardiovascular disease,” Lancet, vol. 384, no. 9943, pp. 618–625, Aug. 2014, doi: 10.1016/S0140-6736(14)61217-4.
52. R. C. Thompson, A. H. Allam, G. P. Lombardi, L. S. Wann, M. L. Sutherland, J. D. Sutherland, M. A. Soliman, B. Frohlich, D. T. Mininberg, J. M. Monge, C. M. Vallodolid, S. L. Cox, G. A. El-Maksoud, I. Badr, M. I. Miyamoto, A. el-Halim Nur el-Din, J. Narula, C. E. Finch, and G. S. Thomas, “Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations,” Lancet, vol. 381, no. 9873, pp. 1211–1222, Apr. 2013, doi: 10.1016/S0140-6736(13)60598-X.
53. H. Kaplan, R. C. Thompson, B. C. Trumble, L. S. Wann, A. H. Allam, B. Beheim, B. Frohlich, M. L. Sutherland, J. D. Sutherland, J. Stieglitz, D. E. Rodriguez, D. E. Michalik, C. J. Rowan, G. P. Lombardi, R. Bedi, C. E. Garcia, J. K. Min, J. Narula, C. E. Finch, M. Gurven, and G. S. Thomas, “Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study,” Lancet, vol. 389, no. 10080, pp. 1730–1739, Apr. 2017, doi: 10.1016/S0140-6736(17)30752-3.